Sleep Apnea, ObstructivesNCT07744854
Development of a Torso Patch Sensor (C-TraQ) as a Companion Device to a Fingertip Sensor (TipTraQ) for Direct Monitoring of Respiratory Effort
An observational study of Sleep Apnea, Obstructives and Sleep Apnea Central, run by PranaQ Pte. Ltd. at 1 site in Taiwan.
Trial summary
The existing PranaQ system utilizes a fingertip sensor that captures PPG(Photoplethysmography) and accelerometer data, and its clinical validation is well-established. While PPG alone has shown effectiveness in diagnosing obstructive sleep apnea, its limited data channels restrict comprehensive evaluation. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sleep Apnea, Obstructives, Sleep Apnea Central
- How many people
- 180 participants
- Where
- 1 siteTaiwan
- Study dates
- 5 Jun 2026to 23 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patient who is scheduled for a sleep study.
Who may be able to join
- Subjects must be 18 years of age or older.
Who cannot join
- Opioids use
- Chronic Obstructive Lung Disease, Global Initiative for Chronic Obstructive
- Lung Disease (GOLD) categorization 3 or 4
- Devastating strokes, with a modified Rankin score (mRS) ≥ 4
- Interstitial lung disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan, 201
Chun-Hsien Tseng Sleep Technician, 886-2-2875-7564, cmd@vghtpe.gov.tw
About this study
Official title: Development and Validation of Chest Patch Sensor for Physiological Signal Measurement and Sleep Apnea Evaluation
The existing PranaQ system utilizes a fingertip sensor that captures PPG(Photoplethysmography) and accelerometer data, and its clinical validation is well-established. While PPG alone has shown effectiveness in diagnosing obstructive sleep apnea, its limited data channels restrict comprehensive evaluation. For instance, it struggles to link apnea events with body position or differentiate between central and obstructive sleep apnea.
To address these limitations, the PranaQ system incorporates new sensors, specifically the chest patch sensor, to monitor respiratory movements via accelerometer signals. The additional respiration signal has the potential to improve diagnostic accuracy for apnea through additional information from respiratory effort.
Read the detailed description
Disease Background Sleep apnea-hypopnea syndrome (SAHS) represents a pervasive and significant public health challenge, affecting a substantial segment of the adult population. Epidemiological data indicate that 34% of men and 17% of women between the ages of 30 and 70 are impacted by this condition. Despite its high prevalence, SAHS remains vastly underdiagnosed and consequently undertreated, leaving a large portion of the affected population vulnerable to its associated health risks.
The established gold standard for the definitive diagnosis of sleep apnea is full-channel polysomnography (PSG). This comprehensive diagnostic procedure necessitates the simultaneous recording of a multitude of physiological and biological signals throughout the night, including electroencephalography (EEG) to monitor brain activity and sleep stages, electrooculography (EOG) for eye movements, electromyography (EMG) for muscle activity, and dedicated sensors for airflow, respiratory effort, and blood oxygen saturation.
However, the clinical utility and accessibility of PSG are severely constrained by several inherent limitations. The study is highly uncomfortable, requiring patients to be affixed with a complex array of over 20 sensors and leads. Crucially, PSG is exclusively a hospital-based procedure, confining patients to an unfamiliar environment which can itself negatively impact natural sleep patterns (the "first-night effect"). Furthermore, the subsequent analysis of the multichannel PSG data is resource-intensive, demanding hours of expert technician time for the meticulous labeling and scoring of individual sleep breathing events, which contributes to its high cost, significant time commitment, and impracticality for widespread population screening or routine follow-up evaluation. These barriers highlight the urgent need for more accessible, less burdensome, and cost-effective diagnostic alternatives for sleep apnea.
Description of PranaQ system
The PranaQ system integrates multiple wearable sensors-one for the fingertip and one for the chest-with a mobile application and an interpretable AI platform. The sensors collect the following data:
- T-TraQ (Fingertip Sensor): Records Photoplethysmography (PPG), accelerometer, and temperature data from the fingertip.
- C-TraQ (Torso Patch Sensor): Also collects PPG, accelerometer, and temperature data. In this study, there are three sensors attached over sternum, abdomen and left subclavicle area.
The PranaQ system, composed of wearable devices and cloud computing, is designed for both home and clinical settings to aid in the evaluation and diagnosis of suspected adult sleep apnea patients, as well as for long-term monitoring. Its function includes recording, storing, and exporting physiological waveforms. After the patient completes the recording, the collected signal data will be sent to the cloud for automatic report generation. The final sleep report will then be sent back to the healthcare provider through a browser-based user interface (PranaQ Expert Panel).
Clinical Evaluation Objectives and Purpose
- Validate the respiration information generated by the C-TraQ (Chest Patch Sensor). The raw signal from the chest patch is accelerometer-based. The respiration rate and waveform generated from the chest patch signal will be compared for consistency with information concurrently obtained from the thorax and abdominal belt collected through the PSG.
- Validate the multi-sensor PranaQ system for the diagnosis of sleep apnea The TST, TRT, ODI, and AHI(both obstructive and central) generated by the PranaQ system will be compared with the results from PSG labeled by a technician.
- Conditions
- Sleep Apnea, Obstructives, Sleep Apnea Central
- Keywords
- apnea, chest patch
- Medical subject headings
- Sleep Apnea Syndromes, Sleep Apnea, Central, Apnea
What is being measured
The primary outcome is the main question the study is designed to answer.
Respiratory Rate
PSG recording estimated respiratory rate as ground truth to compare with the C-TraQ-generated respiratory rate.
Measured: one night
Sleep Position
Sleep Position measured by PSG as ground truth to compare with C-TraQ generated sleep position
Measured: One night
AHI
Technician labeled AHI based on PSG signal to compare with PranaQ system's prediction.
Measured: One night
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2026
- Study start5 Jun 2026
- Primary completion23 Mar 2027 (estimated)
- Study completion23 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sleep Apnea, ObstructivesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- PranaQ Pte. Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07744854
- Sponsor's protocol ID
- C-TraQ developement
- Status last verified
- Jul 2026
- First submitted
- 29 Jul 2026
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of Chest Patch Sensor for Physiological Signal Measurement and Sleep Apnea Evaluation
- ClinicalTrials.gov ID
- NCT07744854
- Acronym / sponsor ID
- C-TraQ developement
- Conditions
- Sleep Apnea, Obstructives, Sleep Apnea Central
- Keywords
- apnea, chest patch
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- PranaQ Pte. Ltd.Industry (pharma, biotech, devices)
- Study start
- 5 Jun 2026 (actual)
- Primary completion
- 23 Mar 2027 (estimated)
- Study completion
- 23 Mar 2027 (estimated)
- First posted
- 4 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The existing PranaQ system utilizes a fingertip sensor that captures PPG(Photoplethysmography) and accelerometer data, and its clinical validation is well-established. While PPG alone has shown effectiveness in diagnosing obstructive sleep apnea, its limited data channels restrict comprehensive evaluation. For instance, it struggles to link apnea events with body position or differentiate between central and obstructive sleep apnea.
To address these limitations, the PranaQ system incorporates new sensors, specifically the chest patch sensor, to monitor respiratory movements via accelerometer signals. The additional respiration signal has the potential to improve diagnostic accuracy for apnea through additional information from respiratory effort.
Detailed description
Disease Background Sleep apnea-hypopnea syndrome (SAHS) represents a pervasive and significant public health challenge, affecting a substantial segment of the adult population. Epidemiological data indicate that 34% of men and 17% of women between the ages of 30 and 70 are impacted by this condition. Despite its high prevalence, SAHS remains vastly underdiagnosed and consequently undertreated, leaving a large portion of the affected population vulnerable to its associated health risks.
The established gold standard for the definitive diagnosis of sleep apnea is full-channel polysomnography (PSG). This comprehensive diagnostic procedure necessitates the simultaneous recording of a multitude of physiological and biological signals throughout the night, including electroencephalography (EEG) to monitor brain activity and sleep stages, electrooculography (EOG) for eye movements, electromyography (EMG) for muscle activity, and dedicated sensors for airflow, respiratory effort, and blood oxygen saturation.
However, the clinical utility and accessibility of PSG are severely constrained by several inherent limitations. The study is highly uncomfortable, requiring patients to be affixed with a complex array of over 20 sensors and leads. Crucially, PSG is exclusively a hospital-based procedure, confining patients to an unfamiliar environment which can itself negatively impact natural sleep patterns (the "first-night effect"). Furthermore, the subsequent analysis of the multichannel PSG data is resource-intensive, demanding hours of expert technician time for the meticulous labeling and scoring of individual sleep breathing events, which contributes to its high cost, significant time commitment, and impracticality for widespread population screening or routine follow-up evaluation. These barriers highlight the urgent need for more accessible, less burdensome, and cost-effective diagnostic alternatives for sleep apnea.
Description of PranaQ system
The PranaQ system integrates multiple wearable sensors-one for the fingertip and one for the chest-with a mobile application and an interpretable AI platform. The sensors collect the following data:
- T-TraQ (Fingertip Sensor): Records Photoplethysmography (PPG), accelerometer, and temperature data from the fingertip.
- C-TraQ (Torso Patch Sensor): Also collects PPG, accelerometer, and temperature data. In this study, there are three sensors attached over sternum, abdomen and left subclavicle area.
The PranaQ system, composed of wearable devices and cloud computing, is designed for both home and clinical settings to aid in the evaluation and diagnosis of suspected adult sleep apnea patients, as well as for long-term monitoring. Its function includes recording, storing, and exporting physiological waveforms. After the patient completes the recording, the collected signal data will be sent to the cloud for automatic report generation. The final sleep report will then be sent back to the healthcare provider through a browser-based user interface (PranaQ Expert Panel).
Clinical Evaluation Objectives and Purpose
- Validate the respiration information generated by the C-TraQ (Chest Patch Sensor). The raw signal from the chest patch is accelerometer-based. The respiration rate and waveform generated from the chest patch signal will be compared for consistency with information concurrently obtained from the thorax and abdominal belt collected through the PSG.
- Validate the multi-sensor PranaQ system for the diagnosis of sleep apnea The TST, TRT, ODI, and AHI(both obstructive and central) generated by the PranaQ system will be compared with the results from PSG labeled by a technician.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patient who is scheduled for a sleep study.
Key inclusion criteria (1 listed)
- Subjects must be 18 years of age or older.
Key exclusion criteria (5 listed)
- Opioids use
- Chronic Obstructive Lung Disease, Global Initiative for Chronic Obstructive
- Lung Disease (GOLD) categorization 3 or 4
- Devastating strokes, with a modified Rankin score (mRS) ≥ 4
- Interstitial lung disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Respiratory Rate
Time frame: one night
PSG recording estimated respiratory rate as ground truth to compare with the C-TraQ-generated respiratory rate.
Sleep Position
Time frame: One night
Sleep Position measured by PSG as ground truth to compare with C-TraQ generated sleep position
AHI
Time frame: One night
Technician labeled AHI based on PSG signal to compare with PranaQ system's prediction.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
Related trials for Sleep Apnea, Obstructives
Not yet recruitingObservational study
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
Obesity & Overweight, Diabetes Mellitus, Type 2
Not yet recruiting
Randomized Clinical Trial for Tonsil Surgery in Adults With Obstructive Sleep Apnea and Enlarged Tonsils
Sleep Apnea, Obstructives, Tonsil Hypertrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sleep Apnea, Obstructives and Sleep Apnea Central, run by PranaQ Pte. Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ke Wei Chen, M.D. (+886-2-77415277, kwchen@pranaq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Respiratory Rate (time frame: one night). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.